MedTrace Logo

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria

NCT05750628 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 327

Last updated 2025-07-30

No results posted yet for this study

Summary

Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria

Conditions

  • Uncomplicated Plasmodium Falciparum Malaria

Interventions

DRUG

INE963

oral INE963

DRUG

KAE609 (Cipargamin)

oral KAE609 (Cipargamin)

DRUG

SoC (Coartem)

SoC (Coartem)

DRUG

KLU156

oral sachet KLU156 (KAF156 + lumefantrine)

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-23
Primary Completion
2026-06-09
Completion
2026-06-23

Countries

  • Burkina Faso
  • Côte d’Ivoire
  • Gabon
  • Ghana
  • Kenya
  • Uganda

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05750628 on ClinicalTrials.gov